A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Advanced Solid Tumor · Pancreatic Adenocarcinoma · Malignant Melanoma (Cutaneous) · Non-small Cell Lung Cancer (NSCLC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 209 (final count)
- Started
- Oct 31, 2022
- Main results expected
- Jun 2027
- Fully finished
- Jun 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Adverse Events
Measured over: From treatment initiation through 30 days following the last IMM-1-104 dose
Phase 1: Dose-Limiting Toxicities
Measured over: The first 21 days of study treatment
Phase 1: Recommended Phase 2 Candidate Optimal Dose
Measured over: Initiation of study treatment through 21 days (up to approximately 18 months)
Phase 2a: Overall Response Rate
Measured over: After up to 48 weeks (12 cycles) of study treatment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05585320 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC